Animal Tumor Models

项目摘要 动物肿瘤模型共享资源（ATM-SR）在三个主要领域提供服务：（i）转基因 和基因敲除小鼠，（ii）临床前肿瘤学，和（iii）动物组织病理学服务。的首要目标 ATM-SR是为了促进斯坦福大学癌症研究所（SCI）进行的高影响力癌症相关研究 通过提供最先进的和全面的动物资源。转基因和基因敲除 1996年，斯坦福大学建立了小鼠生产服务，其总体目标是提供 转基因小鼠模型和相关的支持技术，以成本价提供给斯坦福大学的研究人员， 有效利率。临床前肿瘤学服务，包括研究设计、肿瘤诱导、给药、PK 和PD研究，数据收集和分析，由SCI于2007年发起。这些服务由 转基因，敲除和肿瘤模型中心（TKTC）。兽医服务中心（VSC） 比较医学系管理共享的动物组织病理学服务组件 resource.主要服务包括肿瘤组织学、免疫组织化学和病理学分析 解释。自上次审查以来，动物组织学实验室进行了重大改造， 扩张. 2020年，45%的用户是SCI调查人员。所有项目的成员都定期使用自动取款机- SR，最大的使用来自癌症生物学和癌症干细胞和癌症治疗学 程序.自2015年以来，ATM-SR为超过17篇以癌症为重点的SCI成员出版物做出了贡献; 影响力很大ATM-SR的年度预算为1，250，002美元，而CCSG的要求为105，312美元。 因此，ATM-SR利用了广泛的机构支持，并仅从CCSG资金中寻求8%。的 ATM-SR专注于三个主要的科学目标：（1）生产转基因和基因敲除小鼠，（2）提供 临床前肿瘤学模型服务，以及（3）提供组织病理学服务。

PROJECT SUMMARY The Animal Tumor Models Shared Resource (ATM-SR) provides services in three major areas: (i) transgenic and knockout mice, (ii) preclinical oncology, and (iii) animal histopathology services. The primary goal of the ATM-SR is to facilitate high-impact cancer-relevant research done by Stanford Cancer Institute (SCI) members by providing state-of-the-art and comprehensive animal resources. The transgenic and knockout mouse production services were established at Stanford in 1996 with the overall objective of providing genetically modified mouse models and associated supporting technologies to Stanford investigators at cost- effective rates. Preclinical oncology services, including study design, tumor induction, drug administration, PK and PD study, data collection and analysis, were initiated by the SCI in 2007. These services are provided by the Transgenic, Knockout and Tumor Model Center (TKTC). The Veterinary Service Center (VSC) in the Department of Comparative Medicine manages the animal histopathology service component of the shared resource. Major services include tumor analysis by histology, immunohistochemistry and pathological interpretation. Since the last review, the animal histology laboratory underwent a major renovation and expansion. In 2020, 45% of users were SCI investigators. Members from all programs regularly use the ATM- SR, with the heaviest use coming from the Cancer Biology and Cancer Stem Cells and Cancer Therapeutics programs. The ATM-SR contributed to over 17 cancer-focused SCI member publications since 2015; 10 of them were high-impact. The annual budget of the ATM-SR is $1,250,002 yet the CCSG request is $105,312. Accordingly, the ATM-SR leverages extensive institutional support and seeks only 8% from CCSG funds. The ATM-SR is focused on three major scientific aims: (1) to produce transgenic and knockout mice, (2) to provide preclinical oncology model services, and (3) to provide histopathology services.